RECKITT BENCKIS/S (RBGLY) Receives News Sentiment Rating of 0.25

Press coverage about RECKITT BENCKIS/S (OTCMKTS:RBGLY) has been trending neutral recently, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. RECKITT BENCKIS/S earned a daily sentiment score of 0.25 on their scale. InfoTrie also gave news articles about the company an news buzz score of 10 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock’s share price in the next few days.

Separately, Zacks Investment Research raised RECKITT BENCKIS/S from a “sell” rating to a “hold” rating in a research report on Saturday, September 8th. Two investment analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $21.00.

OTCMKTS:RBGLY traded up $0.62 during mid-day trading on Wednesday, hitting $16.79. The company had a trading volume of 278,232 shares, compared to its average volume of 658,928. The company has a debt-to-equity ratio of 0.75, a current ratio of 0.68 and a quick ratio of 0.50. RECKITT BENCKIS/S has a 1 year low of $15.14 and a 1 year high of $21.79. The firm has a market capitalization of $56.73 billion, a PE ratio of 23.99, a price-to-earnings-growth ratio of 4.17 and a beta of 1.03.

TRADEMARK VIOLATION NOTICE: This report was published by WKRB News and is the sole property of of WKRB News. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.wkrb13.com/2018/11/15/reckitt-benckis-s-rbgly-receives-news-sentiment-rating-of-0-25.html.

RECKITT BENCKIS/S Company Profile

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.

See Also: Hedge Funds Explained

Receive News & Ratings for RECKITT BENCKIS/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RECKITT BENCKIS/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply